MEDIA STATEMENT • MEDIA STATEMENT • MEDIA STATEMENT Investigational heart failure medicine LCZ696 (sacubitril valsartan) receives Promising Innovative Medicine designation in the UK PIM designation is the first s - LCZ696 - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-04-22 09:44:53 Organic chemistry Amides Novartis Carboxylic acids Heart diseases Valsartan Heart failure Enalapril LCZ696 Chemistry Pharmacology ACE inhibitors		MEDIA STATEMENT • MEDIA STATEMENT • MEDIA STATEMENT Investigational heart failure medicine LCZ696 (sacubitril/valsartan) receives Promising Innovative Medicine designation in the UK PIM designation is the first s Add to Reading List Source URL: preview.thenewsmarket.com Download Document from Source Website File Size: 191,86 KB Share Document on Facebook

	Aquis Exchange Monthly Statistics May-2016 € 6,758,607,,245,455 Novartis AG DocID: 1xVO3 - View Document
	Aquis Exchange Monthly Statistics Dec-2015 € 4,614,167,,256,050 Novartis AG DocID: 1xVKG - View Document
	Aquis Exchange Monthly Statistics Apr-2016 € 7,708,388,,903,457 Novartis AG DocID: 1xTdg - View Document
	PDF Document DocID: 1xJ9t - View Document
	PDF Document DocID: 1xzSc - View Document